أحمد محمود عبدالعزيز بندارى
أستاذ مساعد
Efcacy and safety of combination therapy Ezetimibe 10/rosuvastatin 40 in Egyptian patients at very high risk of atherosclerotic cardiovascular disease
The Egyptian Heart Journal • 2025
معلومات البحث
المؤلفون
Mohamed Sobhy, Hala Mahfouz Badran, Mahmoud Hassanein, Samir Rafla, Tarek Zawawy, Amr Zaki, Mohamed Loutfi, Mohamed Sadaka, Sherif Ayad, Amr Kamal, Ahmed Mokhtar & ZEOS investigator group
الكلمات المفتاحية
LDL-C reduction, ESC LDL-C targets, Hyperlipidemia, Rosuvastatin-Ezetimibe
المجلة العلمية
The Egyptian Heart Journal
الناشر
Springer Nature
المجلد
Not Available
العدد
Not Available
الصفحات
Not Available
publication.type
International
رابط البحث
Open Link
المواد المرفقة
Not Available
الملخص
Background
Lipid-lowering therapies (LLT) are well-established in reducing cardiovascular complications and improving outcomes in patients with atherosclerotic cardiovascular disease (ASCVD). However, the efficacy of LLT varies across different ethnic and geographical populations, necessitating further investigation.
Objectives
To evaluate the real-world efficacy and safety of the combination therapy of Ezetimibe 10 mg/Rosuvastatin 40 mg in Egyptian patients at very high risk of ASCVD.
Methods
This multicenter, prospective, single-arm, open-label study enrolled adult patients with documented ASCVD or at very high-risk profiles. Lipid parameters, including total cholesterol (TC), LDL-C, HDL-C, non-HDL-C, and triglycerides, were measured at baseline, 6 weeks, and 12 weeks. The primary endpoint was the proportion of patients achieving the ESC LDL-C target (
Lipid-lowering therapies (LLT) are well-established in reducing cardiovascular complications and improving outcomes in patients with atherosclerotic cardiovascular disease (ASCVD). However, the efficacy of LLT varies across different ethnic and geographical populations, necessitating further investigation.
Objectives
To evaluate the real-world efficacy and safety of the combination therapy of Ezetimibe 10 mg/Rosuvastatin 40 mg in Egyptian patients at very high risk of ASCVD.
Methods
This multicenter, prospective, single-arm, open-label study enrolled adult patients with documented ASCVD or at very high-risk profiles. Lipid parameters, including total cholesterol (TC), LDL-C, HDL-C, non-HDL-C, and triglycerides, were measured at baseline, 6 weeks, and 12 weeks. The primary endpoint was the proportion of patients achieving the ESC LDL-C target (